Health Problems of Civilization
eISSN: 2354-0265
ISSN: 2353-6942
Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO
Current issue Archive Online first About the journal Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
Review paper

LIQUID BIOPSY: REVOLUTIONIZING MINIMAL RESIDUAL DISEASE DETECTION IN LUNG CANCER

Marta Kaus
1
,
Hanna Adamska
2
,
Zuzanna Cudziło
3
,
Karina Grzesik
2
,
Natalia Klepacz
1
,
Marta Malicka
3
,
Weronika Ewa Nowak
3
,
Katarzyna Pilarczyk
2
,
Aleksandra Rabęda
4
,
Hubert Sawczuk
3

  1. Lower Silesian Oncology, Pulmonology and Hematology Center, Wrocław, Poland
  2. Lower Silesian T. Marciniak Specialist Hospital – Center for Emergency Medicine, Wrocław, Poland
  3. Jan Mikulicz-Radecki University Clinical Hospital, Wrocław, Poland
  4. Independent Public Health Care Facility of the Ministry of Internal Affairs and Administration, Kraków, Poland
Health Problems of Civilization
DOI: https://doi.org/10.5114/hpc.2025.151862
Online publish date: 2025/06/18
Article file
- Kaus et al.pdf  [0.71 MB]
Get citation
 
PlumX metrics:
 
1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. https://doi.org/10.3322/caac.21834
2. Isaka T, Adachi H, Murakami K, Miura J, Kikunishi N, Shigeta N, et al. Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: a multicenter study. BMC Cancer. 2023; 23(1): 1064. https://doi.org/10.1186/s12885-023-11582-y
3. Zhong R, Gao R, Fu W, Li C, Huo Z, Gao Y, et al. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis. BMC Med. 2023; 21(1): 180. https://doi.org/10.1186/s12916-023-02849-z
4. Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021; 11(12): 2968-2986. https://doi.org/10.1158/2159-8290.CD-21-0634
5. Chen H, Zhou Q. Detecting liquid remnants of solid tumors treated with curative intent: circulating tumor DNA as a biomarker of minimal residual disease (review). Oncol Rep. 2023; 49(5): 106. https://doi.org/10.3892/or.2023.8543
6. Cortés-Jofré M, Madera M, Tirado-Amador L, Asenjo-Lobos C, Bonfill-Cosp X. Treatments for non-small cell lung cancer: a systematic quality assessment of clinical practice guidelines. Clin Transl Oncol. 2023; 25(12): 3541-3555. https://doi.org/10.1007/s12094-023-03223-4
7. Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024; 93: 102693. https://doi.org/10.1016/j.canep.2024.102693
8. Huang J, Deng Y, Tin MS, Lok V, Ngai CH, Zhang L, et al. Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: a global analysis. Chest. 2022; 161(4): 1101-1111. https://doi.org/10.1016/j.chest.2021.12.655
9. Ma Y, Gan J, Bai Y, Cao D, Jiao Y. Minimal residual disease in solid tumors: an overview. Front Med. 2023; 17(4): 649-674. https://doi.org/10.1007/s11684-023-1018-6
10. Peng Y, Mei W, Ma K, Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol. 2021; 11: 763790. https://doi.org/10.3389/fonc.2021.763790
11. Hendrick RE, Smith RA. Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening. Cancer. 2024; 130(2): 216-223. https://doi.org/10.1002/cncr.34855
12. Ruchalski K, Anaokar JM, Benz MR, Dewan R, Douek ML, Goldin JG. A call for objectivity: radiologists' proposed wishlist for response evaluation in solid tumors (RECIST 1.1). Cancer Imaging. 2024; 24(1): 154. https://doi.org/10.1186/s40644-024-00802-8
13. Ozkara BB, Chen MM, Federau C, Karabacak M, Briere TM, Li J, et al. Deep learning for detecting brain metastases on MRI: a systematic review and meta-analysis. Cancers (Basel). 2023; 15(2): 334. https://doi.org/10.3390/cancers15020334
14. Shahraki Mojahed B, Saravani K, Parooie F. Thoracic staging in patients with non-small cell lung cancer: a systematic review and meta-analysis on diagnostic accuracy of [18F]FDG PET/MRI and [18F]FDG PET/CT. Nucl Med Rev Cent East Eur. 2023; 26(0): 11-19. https://doi.org/10.5603/NMR.a2022.0037
15. Verzè M, Pluchino M, Leonetti A, Corianò M, Bonatti F, Armillotta MP, et al. Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review. Transl Lung Cancer Res. 2022; 11(12): 2588-2600. https://doi.org/10.21037/tlcr-22-390
16. Wen X, Pu H, Liu Q, Guo Z, Luo D. Circulating tumor DNA-a novel biomarker of tumor progression and its favorable detection techniques. Cancers (Basel). 2022; 14(24): 6025. https://doi.org/10.3390/cancers14246025
17. Tellez-Gabriel M, Knutsen E, Perander M. Current status of circulating tumor cells, circulating tumor DNA, and exosomes in breast cancer liquid biopsies. Int J Mol Sci. 2020; 21(24): 9457. https://doi.org/10.3390/ijms21249457
18. Bamodu OA, Chung CC, Pisanic TR. Harnessing liquid biopsies: exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine. J Liquid Biopsy. 2023; 2: 100126. https://doi.org/10.1016/j.jlb.2023.100126
19. Jiang H. Latest research progress of liquid biopsy in tumor – a narrative review. Cancer Manag Res. 2024; 16: 1031-1042. https://doi.org/10.2147/CMAR.S479338
20. Ge Q, Zhang ZY, Li SN, Ma JQ, Zhao Z. Liquid biopsy: comprehensive overview of circulating tumor DNA (Review). Oncol Lett. 2024; 28(5): 548. https://doi.org/10.3892/ol.2024.14681
21. Chang L, Li J, Zhang R. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies. Biochim Biophys Acta Rev Cancer. 2022; 1877(3):188729. https://doi.org/10.1016/j.bbcan.2022.188729
22. Fernandes G, Rodrigues A, Matos C, Barata F, Cirnes L, Ferreira L, et al. Liquid biopsy in the management of advanced lung cancer: implementation and practical aspects. Cancer Treat Res Commun. 2023; 36: 100725. https://doi.org/10.1016/j.ctarc.2023.100725
23. Mishra M, Ahmed R, Das DK, Pramanik DD, Dash SK, Pramanik A. Recent advancements in the application of circulating tumor DNA as biomarkers for early detection of cancers. ACS Biomater Sci Eng. 2024; 10(8): 4740-4756. https://doi.org/10.1021/acsbiomaterials.4c00606
24. Pinzani P, D'Argenio V, Del Re M, Pellegrini C, Cucchiara F, Salvianti F, et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med. 2021; 59(7): 1181-1200. https://doi.org/10.1515/cclm-2020-1685
25. Sheriff S, Saba M, Patel R, Fisher G, Schroeder T, Arnolda G, et al. A scoping review of factors influencing the implementation of liquid biopsy for cancer care. J Exp Clin Cancer Res. 2025; 44(1): 50. https://doi.org/10.1186/s13046-025-03322-w
26. Caputo V, Ciardiello F, Corte CMD, Martini G, Troiani T, Napolitano S. Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. Explor Target Antitumor Ther. 2023; 4(1): 102-138. https://doi.org/10.37349/etat.2023.00125
27. Reina C, Šabanović B, Lazzari C, Gregorc V, Heeschen C. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer. Transl Res. 2024; 272: 41-53https://doi.org/10.1016/j.trsl.2024.05.014
28. Sun Q, Li W, Yang D, Lin PP, Zhang L, Guo H. The presence of small-size circulating tumor cells predicts worse prognosis in non-small cell lung cancer patients. Arch Pathol Lab Med. 2025; 149(1): 39-49. https://doi.org/10.5858/arpa.2023-0455-OA
29. Saini VM, Oner E, Ward MP, Hurley S, Henderson BD, Lewis F, et al. A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer. Mol Oncol. Forthcoming 2024. https://doi.org/10.1002/1878-0261.13705
30. Sadique Hussain M, Gupta G, Ghaboura N, Moglad E, Hassan Almalki W, Alzarea SI, et al. Exosomal ncRNAs in liquid biopsies for lung cancer. Clin Chim Acta. 2025; 565: 119983. https://doi.org/10.1016/j.cca.2024.119983
31. Tang H, Yu D, Zhang J, Wang M, Fu M, Qian Y, et al. The new advance of exosome-based liquid biopsy for cancer diagnosis. J Nanobiotechnology. 2024; 22(1): 610. https://doi.org/10.1186/s12951-024-02863-0
32. Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020; 26(7): 1114-1124. https://doi.org/10.1038/s41591-020-0915-3
33. Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021; 372(6538): eaaw3616. https://doi.org/10.1126/science.aaw3616
34. Rao DY, Huang DF, Si MY, Lu H, Tang ZX, Zhang ZX. Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer. Front Immunol. 2023; 14: 1142539. https://doi.org/10.3389/fimmu.2023.1142539
35. Zhang S, Liu X, Zhou L, Wang K, Shao J, Shi J, et al. Intelligent prognosis evaluation system for stage I-III resected non-small-cell lung cancer patients on CT images: a multi-center study. EClinicalMedicine. 2023; 65: 102270. https://doi.org/10.1016/j.eclinm.2023.102270
36. Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. 2022; 12(7): 1690-1701. https://doi.org/10.1158/2159-8290.CD-21-1486
37. Stergiopoulou D, Markou A, Strati A, Zavridou M, Tzanikou E, Mastoraki S, et al. Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer. Sci Rep. 2023; 13(1): 1258. https://doi.org/10.1038/s41598-022-25400-1
38. Jin Y, Yang F, Chen K. An overview of current development and barriers on liquid biopsy in patients with early-stage non-small-cell Lung cancer. Holist Integ Oncol. 2023; 2: 43. https://doi.org/10.1007/s44178-023-00066-5
39. Zheng H, Wu X, Yin J, Wang S, Li Z, You C. Clinical applications of liquid biopsies for early lung cancer detection. Am J Cancer Res. 2019; 9(12): 2567-2579.
40. Vandekerckhove O, Cuppens K, Pat K, Du Pont B, Froyen G, Maes B. Liquid biopsy in early-stage lung cancer: current and future clinical applications. Cancers (Basel). 2023; 15(10): 2702. https://doi.org/10.3390/cancers15102702
41. Zhou S, Shen C, Wang Y, Zhao Z, Che G. Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review. J Thorac Dis. 2024; 16(7): 4742-4755. https://doi.org/10.21037/jtd-24-265
42. Singal AG, Kurtzman KN, Thompson MJ. Leveraging multi-cancer blood tests to improve diagnostic efficiency for patients with nonspecific signs and symptoms. Future Oncol. 2024; 20(34): 2603-2607. https://doi.org/10.1080/14796694.2024.2388505
43. Sehayek O, Kian W, Onn A, Stoff R, Sorotsky HG, Zemel M, et al. liquid first is "solid" in naïve non-small cell lung cancer patients: faster turnaround time with high concordance to solid next-generation sequencing. Front Oncol. 2022; 12: 912801. https://doi.org/10.3389/fonc.2022.912801
44. Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J Immunother Cancer. 2023; 11(6): e006284. https://doi.org/10.1136/jitc-2022-006284
45. Franzi S, Seresini G, Borella P, Raviele PR, Bonitta G, Croci GA, et al. Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives. Front Genet. 2023; 14: 1254839. https://doi.org/10.3389/fgene.2023.1254839
46. Tomasik B, Skrzypski M, Bieńkowski M, Dziadziuszko R, Jassem J. Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review. Transl Lung Cancer Res. 2023; 12(3): 594-614. https://doi.org/10.21037/tlcr-22-742
47. Heidrich I, Ačkar L, Mohammadi PM, Pantel K. Liquid biopsies: potential and challenges. Int J Cancer. 2021; 148(8): 1795-1807. https://doi.org/10.1002/ijc.33217
48. Jin Y, Mu W, Shi Y, Qi Q, Wang W, He Y, et al. Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG). EClinicalMedicine. 2024; 75: 102769. https://doi.org/10.1016/j.eclinm.2024.102769
49. Duranti L, Tavecchio L, Rolli L, Solli P. New perspectives on lung cancer screening and artificial intelligence. Life (Basel). 2025; 15(3): 498. https://doi.org/10.3390/life15030498
50. Chen K, He Y, Wang W, Yuan X, Carbone DP, Yang F. Development of new techniques and clinical applications of liquid biopsy in lung cancer management. Sci Bull (Beijing). 2024; 69(10): 1556-1568. https://doi.org/10.1016/j.scib.2024.03.062
51. Brockley LJ, Souza VGP, Forder A, Pewarchuk ME, Erkan M, Telkar N, et al. Sequence-based platforms for discovering biomarkers in liquid biopsy of non-small-cell lung cancer. Cancers (Basel). 2023; 15(8): 2275. https://doi.org/10.3390/cancers15082275
52. Foser S, Maiese K, Digumarthy SR, Puig-Butille JA, Rebhan C. Looking to the future of early detection in cancer: liquid biopsies, imaging, and artificial intelligence. Clin Chem. 2024; 70(1): 27-32. https://doi.org/10.1093/clinchem/hvad196
Copyright: © 2025 Pope John Paul II State School of Higher Education in Biała Podlaska. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.